Chief Technology Officer
Dr. Philip Morton has a strong technology background with over 25 years’ experience in the biopharmaceutical industry within process and product development as well as product application research. He was trained as a biochemical engineer and has biopharmaceutical experience in both R&D and manufacturing environments in Albumedix under its former owners of Delta Biotechnology, Aventis and Novozymes. He current heads up biotechnology innovation within Albumedix in both the production and use of its’ products.
- Use of Recombinant Human Albumin in Advanced Therapy Medicinal Products
6 October 2021 9:15 am